Novo Nordisk A/S NVO
41.09 USD +0.39 (+0.96%)
At closeNov 11, 2026, 7:50 PM EST
40.90 -0.19 -0.46%
After hours · Nov 11, 7:50 PM ET
40.10 Day range 41.20
35.12 52-week range 64.16
- YTD
- -19.24%
- 1 year
- -16.40%
News
fool.com JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now? JPMorgan Chase was expecting Novo Nordisk to report strong Wegovy pill sales, and it did. The company's GLP-1 pill sales support the volume-driven business plan, but it is still in a transition phase.
seekingalpha.com Novo Nordisk: Valuations Are Blind To The Upside Novo Nordisk A/S had a broad beat in Q3 2026, with revenue and operating profit having less accounting noise. Successive NVO guidance upgrades seem to have been largely overlooked. Gross-to-net…
benzinga.com Pfizer And Blackstone Life Sciences Enter Co-Funding Agreement Under Which Blackstone Will Pay Up To $1.5B Of Development Costs For Study Of Monthly GLP-1 Receptor Agonist Peptide Berobenatide Through 2028 Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the…
zacks.com ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea Win Eli Lilly's sleep apnea breakthrough amid the FDA's vision-loss warning puts diversified healthcare ETFs in the spotlight.
zacks.com Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock? NVO's Wegovy pill generated DKK 5.4 billion in Q3 sales, boosting obesity growth amid expanding global access and intensifying GLP-1 competition.
247wallst.com Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady Hims and Hers is bouncing back after a brutal selloff, yet the legal heat keeps rising and its two biggest drug suppliers are sitting out the rally. What does the market see that the lawsuit…
247wallst.com Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.
fool.com Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? Eli Lilly has been generating incredible growth in recent quarters due to its top GLP-1 drugs. Novo Nordisk has struggled due to sluggish numbers, but a higher-dose version of Wegovy could change…
zacks.com Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
benzinga.com FDA Flags Potential Vision Loss Risk With GLP-1 Drugs, Requiring Weight-Loss Medicines Like Wegovy and Zepbound to Carry New Warning FDA requires new NAION eye warning on all GLP-1 drugs, citing potential increased risk.
cnbc.com FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of…
globenewswire.com Novo Resources Releases Updated Corporate Presentation PERTH, Australia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate…
benzinga.com Eli Lilly Gains After Jefferies Raises Price Target to Wall Street-High $1,700 Eli Lilly is rising Monday after Jefferies raised its price target to $1,700, the highest target on Wall Street, according to Investing.com.
zacks.com Novo Up 4% in a Month: How Should Investors Approach the Stock Now? NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
reuters.com US FDA orders new eye risk warnings for Ozempic, Zepbound The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and…
fool.com Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide. Novo entered the GLP-1 space ahead of Lilly, but has since lost its lead. Both of these players launched new GLP-1 drugs, the first in pill form, this year.
seekingalpha.com Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth Novo Nordisk is rated BUY with a 6-12 month target price of $57.24, implying ~34% upside from $42.62. Q3 results disprove oral cannibalization fears; a 53% pill surge drove net patient additions,…
fool.com Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now? Novo Nordisk was first to market with a GLP-1 weight-loss shot and pill. Novo Nordisk lost its early lead with the GLP-1 shot to Eli Lilly, but the Wegovy pill seems to be doing well despite Eli…
marketbeat.com What Novo Nordisk A/S (NVO) Said on Its Q3 Earnings Call Novo Nordisk A/S NYSE: NVO raised its 2026 sales and profit outlook after third-quarter adjusted sales rose 4% to DKK 79.2 billion, supported by demand for its obesity treatments and expanding use of…
fool.com Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway? Novo's third-quarter update was strong, largely due to its oral weight-loss pill. The company has several catalysts ahead that could help power strong results over the medium term.
seekingalpha.com 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026) This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our…
prnewswire.com Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026 In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at…
seekingalpha.com Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers,…
benzinga.com 3 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
zacks.com NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook Novo raises its 2026 outlook as Wegovy pill adoption accelerates, while Medicare-driven demand, pricing pressures and 2027 growth remain in focus.
defenseworld.net Stock Traders Purchase High Volume of Novo Nordisk A/S Call Options (NYSE:NVO) Novo Nordisk A/S (NYSE: NVO - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders purchased 63,116 call options on the stock. This represents an increase of 14%…
fool.com Novo Nordisk: 3 Key Takeaways for Long-Term Investors Novo Nordisk added 1.3 million patients in the third quarter. Wegovy pill will reach over 20 markets by mid-2027.
fool.com Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know Novo Nordisk raised its 2026 outlook for the second time in three months, and the stock jumped about 5% on Wednesday. CEO Mike Doustdar wouldn't forecast 2027, but he listed three things helping next…
seekingalpha.com Novo Nordisk A/S (NOVO:CA) Q3 2026 Earnings Call Transcript Novo Nordisk A/S (NOVO:CA) Q3 2026 Earnings Call Transcript
247wallst.com Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices…
zacks.com NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised Novo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Rise as Democrats Take Control of Congress—AMD, AMGN, NVO in Focus (UPDATED) U.S. stocks rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures advanced, following Tuesday's mixed close.
benzinga.com Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines Novo Nordisk (NVO) stock jumped after Q3 earnings beat estimates, driven by record Wegovy pill demand and a raised 2026 outlook.
seekingalpha.com Novo Nordisk Q3: Just The Report I Was Waiting For Novo Nordisk A/S delivered a strong Q3 with a double beat and raised guidance, signaling a turnaround and renewed growth trajectory. Obesity care, especially the Wegovy pill, is driving revenue…
reuters.com GLP-1 drugs help control prediabetes better than current standard medicine Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.
barrons.com 2 Reasons for Hope From Novo Nordisk Earnings The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
marketwatch.com Beleaguered Novo offers relief to investors, thanks to Wegovy pill Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
benzinga.com Novo Nordisk Q3 Adj. EPS $0.87 Beats $0.81 Estimate, Sales $11.900B Beat $11.390B Estimate Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.81 by 7.41 percent. This is a 15.53 percent decrease over earnings of $1.03 per…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds plunge to 22% as Wall Street digests midterm results, a tech futures drop, and key earnings.
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
benzinga.com Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
benzinga.com Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED) Novo Nordisk fails to block Eli Lilly’s weight-loss drug ads as a judge finds little evidence of market impact or lasting harm.
benzinga.com Novo Nordisk To Present 12 New Semaglutide And MASH Research Abstracts At AASLD’s The Liver Meeting 2026 The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASHNew post hoc data…
benzinga.com More Americans Now Take GLP-1 Drugs for Weight Loss Than Diabetes as Food, Alcohol and Apparel Habits Shift, Survey Finds GLP-1 users cut sweets and switch clothing sizes as weight management becomes top use.
benzinga.com Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.
benzinga.com QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.
benzinga.com BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40 BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.
benzinga.com Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’ PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.
benzinga.com FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug FDA extends review for Novo Nordisk's denecimig over manufacturing remediation. Financial outlook remains unchanged with 2027 launch goal.